Good
Mostly Aligned
Patient Risk:
Low
Summary
The response matches core labeled points (AJOVY is a subcutaneous injection; indicated for preventive migraine in adults, and includes pediatric preventive episodic migraine with weight/age criteria; available in prefilled autoinjector and prefilled syringe). Minor completeness issue: pediatric indication weight threshold and episodic nature are not explicitly stated, and contraindications/warnings are not addressed.
Category Scores
Accurate Statements
Ajovy (fremanezumab) is an injection.
Label indicates AJOVY is an injection for subcutaneous use (Dosage Forms and Strengths; injection for subcutaneous use).
Ajovy (fremanezumab) is administered as a subcutaneous (under-the-skin) injection.
AJOVY is for subcutaneous use only (Dosage and Administration). Also described as injection for subcutaneous use (Dosage Forms and Strengths).
Ajovy (fremanezumab) can be given using a prefilled syringe.
Dosage Forms and Strengths: injection: 225 mg/1.5 mL single-dose prefilled syringe.
Ajovy (fremanezumab) can be given using a prefilled autoinjector.
Dosage Forms and Strengths: injection: 225 mg/1.5 mL single-dose prefilled autoinjector.
Unsupported Statements
Ajovy (fremanezumab) is used to prevent migraine.
The label specifies preventive treatment of migraine in adults and preventive treatment of episodic migraine in pediatric patients (age 6–17 and weight 45 kg or more). The statement does not specify episodic pediatric requirement/weight threshold.
Contradictions
Important Omissions
Pediatric indication details are not fully stated: episodic migraine in patients 6–17 years who weigh 45 kg or more, and that AJOVY is not approved for pediatric patients weighing less than 45 kg.
Importance:
Moderate
No labeled dosing regimen is provided (225 mg monthly or 675 mg every 3 months; pediatric 225 mg monthly for eligible patients).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims are limited to formulation/administration and general preventive use, without dosing specifics or safety/contraindication assertions. Missing pediatric eligibility details could affect accurate indication targeting, but no direct unsafe instructions are provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication is not stated with full labeled scope for pediatrics (age/weight and episodic migraine) and does not mention pediatric non-approval for <45 kg; dosing details are omitted.
Suggested Improvement
Refine the indication to match label wording (preventive treatment of migraine in adults and preventive treatment of episodic migraine in pediatric patients 6–17 years who weigh ≥45 kg; not approved for <45 kg) and optionally include labeled dosing options (225 mg monthly or 675 mg every 3 months in adults).